LENSAR

LENSAR Financial Leverage

The Financial Leverage (Equity Multiplier) of LENSAR (LNSR) as of Oct 19, 2026 is -2.75. In the previous year, Financial Leverage (Equity Multiplier) was 3.56 — a change of -177.21% (lower).

Financial Leverage

-2.75

YoY

-177.21%

Last updated:

Financial Leverage (Equity Multiplier) of LENSAR is 2025 -2.75 . Financial Leverage (Equity Multiplier) of LENSAR was 2024 3.56 . It decreases by -177.21% lower compared to the previous year.

The LENSAR Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
-1.41 USD
Jan 1, 2019
-1.13 USD
Jan 1, 2020
1.18 USD
Jan 1, 2021
1.21 USD
Jan 1, 2022
1.33 USD
Jan 1, 2023
1.48 USD
Jan 1, 2024
3.56 USD
Jan 1, 2025
-2.75 USD
The LENSAR Financial Leverage history
YEARFinancial LeverageYoY
-2.75-177.21%
3.56+141.05%
1.48+10.89%
1.33+9.83%
1.21+2.88%
1.18-204.14%
-1.13-19.91%
-1.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR Inc is a healthcare company based in Orlando, Florida, specializing in femtosecond laser technology for refractive cataract surgery. The company went public on September 21, 2020, and currently employs 150 full-time employees. LENSAR develops and markets femtosecond laser systems designed to treat cataracts and manage pre-existing or surgically induced corneal astigmatism. Its primary products include the LENSAR Laser System, which features Streamline IV and IntelliAxis technologies, along with associated consumable components such as a disposable patient interface device kit. The company also offers the ALLY Adaptive Cataract Treatment System, a compact device integrating femtosecond laser capabilities with enhanced laser features for single-room cataract procedures. LENSAR's technology aims to assist surgeons in achieving optimal visual outcomes during cataract surgery. The company operates within the healthcare sector, focusing on innovative solutions for ophthalmic procedures. Its headquarters in Orlando serves as the central hub for research, development, and business operations. LENSAR's website, lensar.com, provides further details about its products and services. The firm's product portfolio emphasizes precision and efficiency in surgical treatments, targeting healthcare providers seeking advanced tools for cataract management. As a publicly traded entity under the ticker LNSR, LENSAR continues to advance its technological offerings in the medical device industry. LENSAR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LENSAR stock

Financial Leverage (Equity Multiplier) of LENSAR is -2.75 in 2025.

Financial Leverage (Equity Multiplier) of LENSAR changed from 3.56 to -2.75, representing a -177.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) LENSAR since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s LENSAR with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — LENSAR

All Key Metrics — LENSAR